The effect of granisetron, a 5-HT3 receptor antagonist, in the treatment of chronic fatigue syndrome patients - A pilot study

Netherlands Journal of Medicine

Volumn 61, Issue 9, 2003, Pages 285-289

  The, G K H ^a   Prins, J ^a   Bleijenberg, G ^a   van der Meer, J W M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GRANISETRON; PLACEBO; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR;

ADULT; AGED; ARTICLE; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; PHYSICAL ACTIVITY; PILOT STUDY; STATISTICAL SIGNIFICANCE; VISUAL ANALOG SCALE; CLASSIFICATION; DRUG ANTAGONISM; PAIN ASSESSMENT; QUESTIONNAIRE;

ADULT; FATIGUE SYNDROME, CHRONIC; FEMALE; GRANISETRON; HUMANS; PAIN MEASUREMENT; PILOT PROJECTS; QUESTIONNAIRES; RECEPTORS, SEROTONIN, 5-HT3;

EID: 1542573915     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The Chronic Fatigue Syndrome Study: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994;121:953-9.
2. Prins JB, Bleijenberg G, Bazelmans E, et al. Cognitive behaviour therapy for chronic fatigue syndrome: a multicentre randomised controlled trial. Lancet 2001;357(9259):841-7.
3. Whiting S, Bagnall A, Sowden A, Cornell J, Mulrow C, Ramirez G. Interventions for the Treatment and Management of Chronic Fatigue Syndrome A Systematic Review. JAMA 2001;286:1360-8.
4. Bakheit A, Behan P, Dinan T, et al. Possible up-regulation of hypothalamic 5-hydroxytryptamine receptors in patients with post-viral fatigue syndrome. J Affect Disorder 1996;41:71-6.
5. Cleare AJ, Bearn J, Allein T, et al. Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. Psychoneuroendocrinology 1995;35:283-9.
6. Sharpe M, Hawton K, Clements A, Cowen PJ. Increased prolactin response to buspirone in chronic fatigue syndrome. J Affect Disord 1996;41:71-6.
7. Sharpe M, Hawton K, Clements A, Cowen P. Increased brain serotonin function in men with chronic fatigue syndrome. BMJ 1997;315:164-5.
8. Vercoulen JHHM, Swanink CMA, Zitman FG, et al. Randomised, placebo-controlled trial of Fluoxetine in chronic fatigue syndrome. Lancet 1996;347:858-61.
9. Jones A. Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. Lancet 1999;354:397.
10. Färber L, Strats W, Brückle W, et al. Efficacy and tolerability of tropisetron in primary fibromyalgia - a highly selective and competitive 5-HT3 receptor antagonist.. Scan J Rheumatol 2000;29(suppl 113):49-54.
11. Papadopoulos IA, Georgiou PE, Katsimbri PP, Drosos AA. Treatment of fibromyalgia with tropisetron, a 5-HT3 serotonin antagonist: a pilot study. Clin Rheumatol 2000;19(1):6-8.
12. Vercoulen JHMM, Swanink CMA, Fennis JFM, Galama JMD, Meer JWM van der, Bleijenberg G. Dimensional assessment of chronic fatigue syndrome. J Psychosom Res 1994;38:383-92.
13. Vercoulen JHMM, Alberts M, Bleijenberg G. De Checklist Individual Strength (CIS). Gedragstherapie 1999;32:131-6.
14. Bergner M, Bobbit RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981;19:787-805.
15. Jacobs HM, Luttik A, Touw-Otten FW, Melker RA de. De sickness impact profile: resultaten van een valideringsonderoek van de Nederlandse versie. Ned Tijdschr Geneeskd 1990;134:1950-4.
16. Werf S van der, Prins J, Vercoulen J, Meer JWM van der, Bleijenberg G. Identifying physical activity patterns in chronic fatigue syndrome in chronic fatigue syndrome using actigraphic assessment. J Psychosom Res 2000;49:373-9.
17. Bazelmans E, Vercoulen J, Galama J, Weel C van, Meer JWM van der, Bleijenberg G. Prevalence of chronic fatigue syndrome and primary fibromyalgia syndrome in the Netherlands. Ned Tijdschr Geneenskd 1997;141:1520-3.
18. Tyron W. Activity measurement in psychology and medicine. New York: Plenum Press, 1991:47-4.
19. Brouwers FM, Werf S van der, Bleijenberg G, Zee L van der, Meer JWM van der. The effect of a polynutrient supplement on fatigue and physical activity of patients with chronic fatigue syndrome: a double-blind randomized controlled trial. QJM 2002;95(10):677-83.
20. Cleare AJ, Bearn J, Allain T, et al. Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. J Affect Disord 1995;34(4):283-9.
21. Parker AJR, Wessely S, Cleare AJ. The neuroendocrinology of chronic fatigue syndrome and fibromyalgia. Psychol Med 2001;31:1331-45.
22. Scott LV, Dinan TG. The neuroendocrinology of chronic fatigue syndrome: focus on the hypothalamic-pituitary-adrenal axis. Funct Neurol 1999;14:3-11.
23. Dursun SM, Blackburn JR, Kutcher SP. An exploratory approach to the serotonergic hypothesis of depression: bridging the synaptic gap. Med Hypotheses 2001;56(2):235-43.
24. Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 1994;40:288-95.
25. Smith KA, Fairburn CG, Cowen PJ. Relapse of depression after rapid depletion of tryptophan. Lancet 1997;349:915-9.